|Day Low/High||236.69 / 238.63|
|52 Wk Low/High||184.50 / 261.27|
Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.
Earnings and hopes for a tax plan help lift the markets. Portfolio moves include exiting a utility position.
Postmenopausal women already have a broad menu of locally administered estrogen therapy products to treat vulvar and vaginal atrophy.
-- Five-Year Study to Enroll 15,000 Adults and Children with NAFLD or NASH --
Doug Kass shares his thoughts on Apple, Allergan and Western Digital.
Some recent high-flying biotechs may be preparing for their next surge.
Political negatives keep popping up, forcing us to rethink the Trump trade, says Jim Cramer.
Campaign educates on the debilitating impact of migraine on patients' everyday lives
These stocks should be part of a strong first-quarter earnings season.
-- Company Recognized with ENERGY STAR Award for Sixth Time --
Doug Kass shares his thoughts on Tesla and the second quarter.
Syria missile strike and U.S. jobs report cap a rugged week for markets. We make several portfolio moves, including a downgrade.
In Recognition of IBS Awareness Month, Allergan and the American Gastroenterological Association Work to Destigmatize the Bowel Health Conversation
BOTOX® is currently being studied as a potential treatment option for adult patients with moderate to severe Major Depressive Disorder (MDD)
Doug Kass shares his thoughts on Caterpillar, Allergan and Oclaro.
This month's resilience in the market has a lot to do with short squeezes in big tech names.
Stocks are mixed on Monday as Wall Street shakes off worries over the way forward for the Trump White House.
The company hired Paul Bisaro, former chairman at Allergan, to become CEO as Morgan Stanley helps explore alternatives, including a sale.
The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 5,524,975 share decrease in total short interest for Allergan PLC , to 8,520,757, a decrease of 39.34% since 02/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Shares of Allergan are gaining for the third straight session and, at midday, are trading above last week's high.
Stocks fall on Monday morning as Donald Trump's failure to push through health care reform raises doubts over his ability to enact other promised changes.
Paratek Pharmaceuticals soared while Foamix floundered ahead of market's open.